Cargando…

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS

OBJECTIVE: This phase I study investigated pharmacokinetic (PK) and pharmacodynamic (PD) profiles of natalizumab in pediatric patients with relapsing-remitting MS (RRMS). METHODS: Pediatric patients with RRMS who were prescribed natalizumab 300 mg IV every 4 weeks were enrolled. Blood samples were c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghezzi, Angelo, Comi, Giancarlo, Grimaldi, Luigi Maria, Moiola, Lucia, Pozzilli, Carlo, Fantaccini, Simone, Gallo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624146/ https://www.ncbi.nlm.nih.gov/pubmed/31355324 http://dx.doi.org/10.1212/NXI.0000000000000591

Ejemplares similares

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
por: Prosperini, Luca, et al.
Publicado: (2019)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab
por: Wang, Y. C., et al.
Publicado: (2011)

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies
por: Sehr, T., et al.
Publicado: (2016)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach
por: Julian, Guilherme Silva, et al.
Publicado: (2020)

Cortical Pathology in RRMS: Taking a Cue from Four Sisters
por: Calabrese, Massimiliano, et al.
Publicado: (2012)

Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
por: Foley, John F., et al.
Publicado: (2020)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
por: Flores-Pérez, Carmen, et al.
Publicado: (2023)

Oral available agents in the treatment of RRMS
por: Aupérin, Thierry
Publicado: (2013)

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only
por: Kalra, S, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy
por: Giacoppo, Sabrina, et al.
Publicado: (2017)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

Distinct binding properties of TIAR RRMs and linker region
por: Kim, Henry S., et al.
Publicado: (2013)

Randomized trial of daily high-dose vitamin D(3) in patients with RRMS receiving subcutaneous interferon β-1a
por: Hupperts, Raymond, et al.
Publicado: (2019)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of fenoldopam mesylate for blood pressure control in pediatric patients
por: Hammer, Gregory B, et al.
Publicado: (2008)

Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
por: Ward, Robert M., et al.
Publicado: (2013)

Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma
por: Takechi, Tomoki, et al.
Publicado: (2018)

Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
por: Lee, Soyoung, et al.
Publicado: (2023)

2946. Comparative Pharmacokinetics and Pharmacodynamics of Cefadroxil and Cephalexin for Pediatric Musculoskeletal Infections
por: Haynes, Andrew, et al.
Publicado: (2023)

Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization
por: De Stefano, Nicola, et al.
Publicado: (2021)

Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics
por: Lecca, Paola, et al.
Publicado: (2012)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
por: Vališ, Martin, et al.
Publicado: (2020)

Simulation Training to Improve Informed Consent and Pharmacokinetic/Pharmacodynamic Sampling in Pediatric Trials
por: Burckhardt, Bjoern B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1kjtjldb9k0k6b26moo2lk2dfq